Thank you, and good afternoon, everyone, and welcome to Finance Of America Companies Inc.'s fourth quarter and full year 2025 earnings call. With me today are Graham A. Fleming, Chief Executive ...
Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) ...
YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 - - Company earned $35.6 million in total revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results